A2 Bio Announces First Patient Dosed in Phase 1 Clinical Trial of A2B530, a Novel Cell Therapy for the Treatment of Colorectal, Pancreatic and Non-small Cell Lung Cancers

AGOURA HILLS, Calif.–(BUSINESS WIRE)– #A2Bio–First-in-human trial using A2 Bio’s logic-gated Tmod™ platform to provide selective killing of tumor cells while protecting normal cells